Submitted:
27 December 2025
Posted:
29 December 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Literature Search Strategy
2.2. Search Terms
- ("cleaning validation" OR "cleaning verification") AND ("HPLC" OR "high-performance liquid chromatography")
- ("cleaning validation" OR "cleaning verification") AND ("TOC" OR "total organic carbon")
- ("pharmaceutical manufacturing") AND ("residue detection") AND ("analytical methods")
- ("cross-contamination") AND ("GMP") AND ("analytical validation")
2.3. Inclusion and Exclusion Criteria
- Peer-reviewed original research articles, review papers, and technical reports
- Studies comparing or evaluating HPLC and/or TOC for cleaning validation applications
- Regulatory guidance documents from FDA, EMA, WHO, and PIC/S
- Industry white papers from recognized pharmaceutical associations
- Non-English publications
- Studies focused exclusively on non-pharmaceutical applications
- Conference abstracts without full-text availability
- Publications predating 2010 (unless seminal works)
2.4. Data Extraction and Analysis
3. Results and Discussion
3.1. Fundamental Principles and Detection Mechanisms
3.1.1. High-Performance Liquid Chromatography (HPLC)
3.1.2. Total Organic Carbon (TOC) Analysis
3.2. Comparative Analytical Performance
3.2.1. Specificity and Selectivity
- Multiple APIs are manufactured on shared equipment
- Degradation products require separate quantification
- Regulatory requirements mandate specific API residue limits based on toxicological assessment
- Detection of all organic residues (including cleaning agents and degradation products) is desired
- Rapid screening of equipment cleanliness is required
- Product changeover involves chemically similar compounds with comparable toxicological profiles
3.2.2. Sensitivity and Detection Limits
3.2.3. Precision and Accuracy
3.3. Regulatory Perspectives and Compliance Considerations
3.3.1. FDA Guidance
- Methods must be validated according to ICH Q2(R1) guidelines
- Detection limits must be adequate to quantify residues at levels below established acceptance criteria
- Recovery studies must demonstrate the effectiveness of sampling procedures
- Specificity requirements should be commensurate with the intended use
- The acceptance limit is based on the TOC response of the most difficult-to-detect compound
- Cleaning procedures are demonstrated to remove cleaning agents to acceptable levels
- The validation protocol includes scientific justification for method selection [20]
3.3.2. EMA and PIC/S Requirements
- Product toxicological profile and therapeutic index
- Equipment design and cleanability
- Cleaning procedure effectiveness
- Sampling method recovery efficiency
3.4. Practical Implementation Considerations
3.4.1. Method Development Requirements
- Chromatographic condition optimization (mobile phase, column, temperature)
- System suitability parameter establishment
- Forced degradation studies to demonstrate stability-indicating capability
- Matrix effect evaluation for each equipment type and product combination
- Instrument calibration and linearity verification
- System suitability using standard solutions
- Recovery studies for specific equipment and sampling procedures
3.4.2. Throughput and Turnaround Time
- Rapid equipment release is critical for production scheduling
- Multiple sample points require analysis per cleaning event
- Real-time decision-making regarding re-cleaning is necessary
3.4.3. Cost Considerations
3.5. Application-Specific Recommendations
3.5.1. Scenarios Favoring HPLC
- High-potency API (HPAPI) manufacturing: The enhanced specificity and sensitivity of HPLC (particularly HPLC-MS) is essential for demonstrating compliance with extremely low acceptance criteria (ng/cm² range) typical of HPAPI cleaning validation [25].
- Toxicological limit-based approaches: When MAC calculations are based on compound-specific toxicological data (Permitted Daily Exposure, PDE), specific quantification of the residual API is required to demonstrate compliance.
- Degradation product monitoring: Facilities requiring separate quantification of API and degradation products must employ chromatographic methods capable of compound differentiation.
- Regulatory requirements mandating specific detection: Certain products or markets may have explicit regulatory requirements for specific analytical methods.
3.5.2. Scenarios Favoring TOC
- Multi-product facilities with diverse portfolios: The non-specific nature of TOC eliminates the need for compound-specific method development, providing substantial efficiency gains for facilities manufacturing numerous products [26].
- Cleaning agent residue detection: TOC effectively detects organic cleaning agents (surfactants, solvents) that may not be readily detectable by HPLC methods developed for API quantification.
- Rapid turnaround requirements: Facilities requiring rapid equipment release benefit from the shorter analysis times of TOC.
- Visual cleanliness correlation: When cleaning procedures result in visually clean equipment and TOC provides confirmation of overall organic contamination removal.
3.5.3. Combined Approach Strategies
- Tier 1 (Routine Verification): TOC analysis for rapid, non-specific screening of all cleaning events
- Tier 2 (Periodic Validation): HPLC analysis at defined intervals to confirm specific API removal
- Tier 3 (Investigation): HPLC deployment for out-of-specification investigations or process changes
4. Conclusions
- Validation objectives: Specific API quantification versus total organic contamination assessment
- Product portfolio characteristics: Potency, toxicological profiles, and chemical diversity
- Regulatory requirements: Market-specific expectations and precedent
- Operational considerations: Throughput requirements, resource availability, and cost constraints
5. Recommendations for Implementation
- Conduct a comprehensive risk assessment considering product portfolio, equipment characteristics, and operational requirements before selecting primary analytical methodology.
- Establish acceptance criteria using a scientifically justified approach (toxicological, dose-based, or general limit) and ensure selected analytical methods possess adequate sensitivity.
- Validate all analytical methods according to ICH Q2(R1) guidelines, with particular attention to recovery studies using production-representative sampling procedures.
- Consider a tiered approach utilizing TOC for routine verification and HPLC for periodic confirmation or specific applications requiring compound identification.
- Document the scientific rationale for method selection in cleaning validation protocols to support regulatory inspections.
- Maintain ongoing evaluation of analytical program effectiveness through trend analysis and periodic reassessment of method suitability.
6. Future Perspectives
- Direct Surface Analysis: Techniques such as DART-MS (Direct Analysis in Real Time Mass Spectrometry) enable direct surface interrogation without swab extraction [28].
- Spectroscopic Methods: Near-infrared (NIR) and Raman spectroscopy offer potential for rapid, non-destructive surface analysis.
- Electrochemical Sensors: Development of compound-specific sensors may enable real-time, in-situ monitoring of cleaning effectiveness.
- Machine Learning Integration: Application of artificial intelligence to spectroscopic data may enhance both specificity and throughput of non-destructive methods.
Conflicts of Interest
References
- Food and Drug Administration. (1993). Guide to inspections of validation of cleaning processes. Office of Regulatory Affairs, FDA. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/validation-cleaning-processes-793.
- Bismuth, G., & Neumann, S. (2000). Cleaning validation: A practical approach. CRC Press.
- Vaghela, U. (2025). Risk-based cleaning validation in pharmaceutical manufacturing: A comprehensive review. International Journal of Multidisciplinary Research and Growth Evaluation, 6(6), 1067–1073. [CrossRef]
- LeBlanc, D. A. (2020). Cleaning validation: Practical compliance solutions for pharmaceutical manufacturing. Pharmaceutical Technology, 44(7), 32–38. https://www.pharmtech.com.
- Snyder, L. R., Kirkland, J. J., & Dolan, J. W. (2011). Introduction to modern liquid chromatography (3rd ed.). John Wiley & Sons. [CrossRef]
- Jenkins, K. M., Vanderwielen, A. J., Armstrong, J. A., Leonard, L. M., Murphy, G. P., & Piros, N. A. (1996). Application of total organic carbon analysis to cleaning validation. PDA Journal of Pharmaceutical Science and Technology, 50(1), 6–15. https://journal.pda.org/content/50/1/6.
- Fourman, G. L., & Mullen, M. V. (1993). Determining cleaning validation acceptance limits for pharmaceutical manufacturing operations. Pharmaceutical Technology, 17(4), 54–60.
- Liu, C., & Hwang, R. C. (2009). Total organic carbon as a universal method for cleaning validation. Pharmaceutical Engineering, 29(4), 1–8.
- Food and Drug Administration. (1993). Guide to inspections validation of cleaning processes (7/93). Office of Regulatory Affairs, FDA. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/validation-cleaning-processes-793.
- European Commission. (2015). EudraLex Volume 4, Annex 15: Qualification and validation. European Commission Health and Consumers Directorate-General. https://health.ec.europa.eu/system/files/2016-11/2015-10_annex15_0.pdf.
- Meyer, V. R. (2010). Practical high-performance liquid chromatography (5th ed.). John Wiley & Sons. [CrossRef]
- Natishan, T. K. (2004). Developments in liquid chromatography/mass spectrometry for pharmaceutical analysis. Journal of Pharmaceutical and Biomedical Analysis, 35(5), 1213–1222. [CrossRef]
- Clesceri, L. S., Greenberg, A. E., & Eaton, A. D. (1998). Standard methods for the examination of water and wastewater (20th ed.). American Public Health Association.
- Shimadzu Corporation. (2020). Total organic carbon (TOC) analysis: Principles and applications. Technical Bulletin.
- Mirza, T., Lunn, M. J., Keeley, F. J., George, R. C., & Bodenmiller, J. R. (1999). Cleaning level acceptance criteria and a high-pressure liquid chromatography procedure for the assay of meclizine hydrochloride residue in swabs collected from pharmaceutical manufacturing equipment surfaces. Journal of Pharmaceutical and Biomedical Analysis, 19(5), 747–756. [CrossRef]
- Walsh, A., Mayer, P., & Schultz, T. (2013). Practical considerations for cleaning validation in multi-product facilities. Journal of GXP Compliance, 17(4), 64–72.
- Hwang, R. C., Lin, Y., & Horwitz, W. (2013). Statistical approaches for establishing cleaning validation acceptance criteria and assessing cleaning performance. Journal of Validation Technology, 19(2), 1–12.
- International Council for Harmonisation. (2005). ICH Q2(R1): Validation of analytical procedures: Text and methodology. ICH Harmonised Tripartite Guideline. https://database.ich.org/sites/default/files/Q2(R1)%20Guideline.pdf.
- Li, X., Ahmad, I. A. H., Tam, J., Wang, Y., Dao, G., & Blasko, A. (2018). Cleaning verification: A five parameter study of a total organic carbon method development and validation for the cleaning assessment of residual detergents in manufacturing equipment. Journal of Pharmaceutical and Biomedical Analysis, 149, 33–39. [CrossRef]
- Food and Drug Administration. (2021). Warning letters database. FDA Office of Regulatory Affairs. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters.
- Pharmaceutical Inspection Co-operation Scheme. (2007). PI 006-3: Recommendations on validation master plan, installation and operational qualification, non-sterile process validation, cleaning validation. PIC/S Secretariat. https://picscheme.org/docview/3447.
- Westman, L., & Karlsson, G. (2007). Methods for detecting cleaning agent residuals and their applications in pharmaceutical cleaning validation. Journal of Pharmaceutical and Biomedical Analysis, 43(5), 1589–1597. [CrossRef]
- Thomas, O., & Burgess, C. (2017). UV-visible spectrophotometry of water and wastewater (2nd ed.). Elsevier. [CrossRef]
- Hall, W., & Zahn, M. (2016). Cleaning validation in pharmaceutical industry. In Cleanroom technology (pp. 261–290). CRC Press.
- Nasr, M., & Raza, A. (2020). Cleaning validation strategies for highly potent active pharmaceutical ingredients. AAPS PharmSciTech, 21(4), 135. [CrossRef]
- LeBlanc, D. A. (2000). Validated cleaning technologies for pharmaceutical manufacturing. Interpharm Press.
- Kumar, V., Rathore, A. S., & Bharadwaj, R. (2021). Cleaning validation for biopharmaceutical manufacturing: A comprehensive review. Biotechnology Progress, 37(2), e3097. [CrossRef]
- Cody, R. B., Laramée, J. A., & Durst, H. D. (2005). Versatile new ion source for the analysis of materials in open air under ambient conditions. Analytical Chemistry, 77(8), 2297–2302. [CrossRef]
- Valavala, S., Seelam, N., Tondepu, S., & Sundaramurthy, V. (2020). Cleaning method validation for estimation of dipyridamole residue on the surface of drug product manufacturing equipment using swab sampling and by high performance liquid chromatographic technique. Turkish Journal of Pharmaceutical Sciences, 17(2), 182–189. [CrossRef]
- Moura, M. J., Pereira, A. D., & Santos, D. J. F. (2025). Cleaning validation in pharmaceutical quality control laboratories: A structured protocol for contamination.
| Parameter | HPLC-UV | HPLC-MS | TOC |
| Typical LOD | 0.1–1.0 µg/mL | 0.001–0.1 µg/mL | 0.05–0.5 mg/L C |
| Typical LOQ | 0.5–5.0 µg/mL | 0.01–0.5 µg/mL | 0.1–1.0 mg/L C |
| Sample Volume | 10–100 µL | 1–20 µL | 5–25 mL |
| Analysis Time | 15–60 min | 10–30 min | 3–8 min |
| Cost Factor | HPLC | TOC |
| Instrument Capital Cost | $30,000–$150,000 | $20,000–$60,000 |
| Annual Maintenance | $5,000–$15,000 | $2,000–$8,000 |
| Consumables (annual) | $10,000–$30,000 | $3,000–$10,000 |
| Method Development (per compound) | $5,000–$20,000 | $1,000–$5,000 |
| Analyst Training | Extensive | Moderate |
| Sample Analysis Cost | $20–$100 | $5–$25 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.